NTLA — Intellia Therapeutics Inc

Intellia Therapeutics Inc (NTLA) is a biotechnology company listed on NASDAQ. It is led by John M. Leonard M.D., based in 40 Erie Street, Cambridge, MA, United States, 02139, with about 403 employees. Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 that is in Phase 1/2 study for the treatment of hereditary angioedema. It also focusses on the research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Latest reported NTLA revenue for 2025-09-30 was $13.8M. Net income was -$316.9M. Revenue was down 3.3% from 2025-06-30 to 2025-09-30. NTLA currently screens at market cap $1.19B.

Use this NTLA page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the NTLA quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the NTLA SEC filings page. Lician reads the product cache first so this HTML stays unique to Intellia Therapeutics Inc even when a live quote feed is slow.